REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

Last updated: February 22, 2016
Sponsor: Immune Response BioPharma, Inc.
Overall Status: Trial Status Unknown

Phase

3

Condition

Hiv

Treatment

N/A

Clinical Study ID

NCT02366026
IR103-007
  • Ages > 16
  • All Genders

Study Summary

The primary objective is to compare & evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts & CD4+ & CD8+ T cell counts along with increased HIV immunity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are HIV-positive and started anti-HIV drugs soon after tests showed the presence ofHIV.

  • Are at least 16 years old (consent of parent or guardian required if under 18 years).

Exclusion

Exclusion Criteria:

  • Healthy Subjects

  • Currently abuse alcohol or drugs.

Study Design

Total Participants: 500
Study Start date:
June 01, 2017
Estimated Completion Date:
June 30, 2019

Study Description

This is a 500 subject Multi Center double-blind randomized, Safety & Efficacy, HIV/AIDS Phase III study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen & Amplivax compared to placebo group Amplivax in viral load, and secondarily to examine changes in CD4+ & CD8+ T cell counts, determine Remune vaccines effect of multiple inoculations of HIV-1 immunogen + Amplivax on viral replication in adults with HIV-1 infection & to examine immunogenicity of Remune + Amplivax in a Multi-center, randomized , double-blind, placebo-controlled, two arm parallel design study of Remune + Amplivax.

Connect with a study center

  • Clinical Site TBA

    San Diego, California 92101
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.